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Viruses are detected by different classes of pattern recog-
nition receptors (PRRs), such as Toll-like receptors and
RIG-like helicases. Engagement of PRRs leads to activation
of interferon (IFN)-regulatory factor 3 (IRF3) and IRF7
through IKKe and TBK1 and consequently IFN-b induction.
Vaccinia virus (VACV) encodes proteins that manipulate
host signalling, sometimes by targeting uncharacterised
proteins. Here, we describe a novel VACV protein, K7,
which can inhibit PRR-induced IFN-b induction by pre-
venting TBK1/IKKe-mediated IRF activation. We identified
DEAD box protein 3 (DDX3) as a host target of K7.
Expression of DDX3 enhanced Ifnb promoter induction
by TBK1/IKKe, whereas knockdown of DDX3 inhibited
this, and virus- or dsRNA-induced IRF3 activation. Further,
dominant-negative DDX3 inhibited virus-, dsRNA- and
cytosolic DNA-stimulated Ccl5 promoter induction, which
is also TBK1/IKKe dependent. Both K7 binding and
enhancement of Ifnb induction mapped to the N-terminus
of DDX3. Furthermore, virus infection induced an associa-
tion between DDX3 and IKKe. Therefore, this study shows
for the first time the involvement of a DEAD box helicase
in TBK1/IKKe-mediated IRF activation and Ifnb promoter
induction.
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Introduction
The innate immune response to viruses is critically depen-
dent on their recognition by pattern recognition receptors
(PRRs), which induce the production of type I interferons
(IFNs). The different classes of PRRs implicated in this
process include Toll-like receptors (TLRs), RIG-like helicases
(RLHs) and cytosolic DNA receptors (Takaoka and Taniguchi,
2007). TLR3, 7, 8 and 9 constitute a subset of TLRs that
localise to the endosomal compartment and recognise viral
nucleic acids: TLR3 responds to dsRNA, TLR7 and 8 to
ssRNA, and TLR9 to unmethylated CpG dsDNA (Bowie,
2007). In contrast, the RLHs recognise viral RNA in the
cytoplasm. Retinoic acid-inducible gene I (RIG-I) and
melanoma differentiation-associated gene 5 (Mda-5) bind
distinct viral dsRNAs and thereby recognise the different
RNA viruses (Hornung et al, 2006; Kato et al, 2006;
Pichlmair et al, 2006). An antiviral response can also be
induced by cytoplasmic dsDNA through one or more recep-
tor(s) that are independent of RIG-I and Mda-5 (Takaoka and
Taniguchi, 2007). DNA-dependent activator of IFN-regulatory
factors (IRFs) (DAI, also called DLM-1, ZBP1) has been
implicated in this (Takaoka et al, 2007), although additional
DNA receptors seem to be involved in vivo (Ishii et al, 2008).
All of these antiviral PRRs signal to the activation of
transcription factors required for type I IFN induction,
namely NF-kB, IRF3 and 7 (O’Neill, 2006). The upstream
signalling pathways are distinct for different PRRs. Signalling
from TLR3 and 4 to IRF3 and 7 activation involves the
adaptor protein TRIF, whereas TLR7, 8 and 9 signal to
these IRFs through MyD88 and interleukin-1 (IL-1) recep-
tor-associated kinase 1 (IRAK1) (Moynagh, 2005). The RLHs
signal to IRF activation through the CARD-domain-containing
adaptor molecule MAVS (mitochondrial antiviral signalling,
also called Cardif, VISA and IPS-1) (Yoneyama et al, 2004;
Kawai et al, 2005; Meylan et al, 2005; Seth et al, 2005; Xu
et al, 2005) while signalling adaptors for DAI and potential
additional DNA receptor(s) have not yet been identified. Most
of these PRR pathways (with the exception of TLR7, 8 and 9)
converge at the level of IKKe and/or TBK1, the kinases
that lead to the phosphorylation and activation of IRF3 and
7, placing them at the central point of the IRF activation
pathways.
In the process of co-evolution with the host, viruses have
developed sophisticated mechanisms to evade or subvert key
aspects of the host antiviral response. Therefore, the study of
viral evasion mechanisms can help to identify novel aspects
of the host antiviral response. For example, the description of
the vaccinia virus (VACV) TLR antagonists A46 and A52
provided evidence for the involvement of TLRs in the anti-
viral response (Bowie et al, 2000; Harte et al, 2003; Stack
et al, 2005). A52 interacts with the TLR signalling compo-
nents TNF-receptor-associated factor 6 (TRAF6) and IRAK2
(Harte et al, 2003; Maloney et al, 2005). By interacting with
TRAF6, A52 can stimulate p38 MAP kinase activation and
enhance TLR-mediated induction of the anti-inflammatory
cytokine IL-10 (Maloney et al, 2005), whereas it inhibits TLR-
induced NF-kB activation and pro-inflammatory cytokine
production through targeting of IRAK2 (Keating et al, 2007).
We became interested in another as yet uncharacterised
VACV protein, K7, because it shares significant sequence
similarity with A52 and is very well conserved within the
poxvirus family. Here, we show that K7 mimics some of the
effects of A52 and shares its intracellular targets. However,
unlike A52, K7 also has a potent inhibitory effect on TLR-
dependent and -independent IRF activation and consequently
Ifnb promoter induction, which suggests it might target
additional host proteins. We identify the DEAD box protein
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(DDX3) as a target of K7 and show that DDX3 has a novel role
in Ifnb promoter induction. DDX3 is an RNA helicase, and the
human protein and/or its orthologues have previously been
implicated in diverse cellular processes, including splicing,
translational regulation, nuclear export of RNA (Rosner and
Rinkevich, 2007) and more recently in cancer biogenesis
(Botlagunta et al, 2008). Interestingly, DDX3 is also targeted
by other viral proteins, namely hepatitis C virus (HCV) core
protein (Mamiya and Worman, 1999; Owsianka and Patel,
1999; You et al, 1999) and HIV Rev (Yedavalli et al, 2004).
HIV exploits the nucleocytoplasmic shuttling capacity of
DDX3 for exporting its mRNAs out of the nucleus (Yedavalli
et al, 2004), and DDX3 may also be required for HCV
replication (Ariumi et al, 2007).
In this study, expression of DDX3 led to enhanced
TBK1/IKKe-dependent Ifnb promoter induction, whereas sup-
pression of DDX3 expression by RNAi inhibited this, as well
as virus or poly(I:C)-induced IRF3 activation. This function of
DDX3 required its N-terminal region, which correlated with
the region that was targeted by K7. Further, virus infection
stimulated the association of DDX3 and IKKe. Thus, we
demonstrate an unexpected novel role for the DEAD box
helicase DDX3 in Ifnb promoter induction and provide evi-
dence that this function is targeted by a viral evasion strategy.
Results
Identification of K7
K7 was identified from an analysis of poxvirus genomes as
having significant sequence similarity to the TLR antagonist
A52. A52 (VACV_WR178) is a 190 amino-acid (aa) protein,
whereas K7 (VACV_WR039) is only 149 aa long. An align-
ment of A52 and K7 from the VACV strain Western Reserve
(WR) shows 26% aa identity and 45% similarity within the
shared region of sequence (Figure 1A). Analysis of available
K7 orthopoxvirus sequences (www.poxvirus.org) showed
that K7 is highly conserved between different viruses, dis-
playing greater than 95% aa identity between orthologues
(Figure 1B), suggesting an important function for K7.
To characterise the function of K7, K7R from VACV strain
WR (VACV_WR039) was cloned into a mammalian expres-
sion vector containing an N-terminal HA epitope (pCMV-HA-
K7R). Transfection of increasing amounts of pCMV-HA-K7R
into HEK293T cells led to a concomitant increase in K7
expression at its predicted molecular mass of 17.5 kDa
(Figure 1C). We then generated a rabbit polyclonal antiserum
against K7 to confirm K7 protein expression in VACV WR-
infected HEK293T cells. The expression of K7 was visible as
early as 2 h post-infection (p.i.) and increased until 24 h p.i.
(Figure 1D).
K7 inhibits TLR-induced NF-jB activation and gene
expression
Given its similarity to A52, we tested whether K7 affected NF-
kB activation induced by IL-1R/TLR signalling. Similar to
A52, K7 expression inhibited IL-1-induced activation of the
NF-kB reporter in a dose-dependent manner (Figure 2A).
Also similar to A52, expression of K7 inhibited NF-kB activa-
tion induced by TLR4 (the constitutively active CD4-TLR4
fusion receptor) (Figure 2B) and TLR3 (activated by its
synthetic dsRNA ligand poly(I:C) (Figure 2C). K7 also inhib-
ited NF-kB-dependent chemokine expression, namely LPS-
induced IL-8 production (Figure 2D) and poly(I:C)-induced
RANTES production (Figure 2E).
As both K7 and A52 affected the TLR–NF-kB axis, we
investigated whether K7 shares intracellular targets with A52,
namely IRAK2 and TRAF6 (Harte et al, 2003). K7 co-immu-
noprecipitated with IRAK2 when both proteins were co-
expressed in HEK293T cells (Figure 2F, upper panel, lanes 6
and 9). Similarly, K7 co-immunoprecipitated with TRAF6
(Figure 2G, upper panel, lane 3), but did not interact with
TRAFs 1–5 (Figure 2G, upper panel, lanes 6, 9, 12, 15 and
Figure 1 Identification and expression of K7. (A) Alignment of A52 (VACV_WR178) and K7 (VACV_WR039) proteins from VACV (WR strain).
(B) Alignment of K7 orthologues. VACV-WR: VACV Western Reserve; VACV-AMVA: VACV-Acambis 3000 MVA; VACV-COP: VACV Copenhagen;
VACV-MVA: VACV modified virus Ankara; VACV-TAN: VACV Tian Tan; RPXV-UTR: rabbitpox virus Utrecht; VARV-BSH: variola virus
Bangladesh; VARV-GAR: variola virus Garcia; VARV-India, variola virus India; CMLV-CMS: camelpox virus CMS; CMLV-M96: camelpox
virus M96; CPXV-BR: cowpox virus Brighton red; MPXV-ZRE: monkeypox virus Zaire. (C) VACVWR K7Rwas cloned into pCMV-HA. Increasing
amounts of pCMV-HA-K7R DNAwere transfected into HEK293T cells, and 48h later K7 expression was analysed by immunoblotting using an
anti-HA antibody. (D) HEK293 cells infected with VACV WR at 10 p.f.u. per cell were harvested at the indicated times post-infection and lysates
were analysed by immunoblotting using K7-specific antiserum.
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18). Similar to A52 (Harte et al, 2003), K7 co-immunopreci-
pitated with the TRAF domain of TRAF6 (aa 289–522) (not
shown).
K7, but not A52, inhibits IRF activation induced by TLR
and non-TLR pathways
In contrast to the seemingly redundant effect of K7 and A52
on the TLR–NF-kB axis, a crucial difference between the two
proteins became apparent when we investigated the effect of
K7 on the signalling pathway leading to IRF activation. TLR3
and 4 stimulate IRF3 and 7 activation through TRIF, which is
insensitive to A52 inhibition (Figure 3A and B), as TRAF6 and
IRAK2 are not involved in this pathway (Keating et al, 2007).
K7 strongly inhibited TRIF-induced activation of IRF3 and 7
(Figure 3A and B), thus revealing a key difference between
A52 and K7.
We next tested whether K7 also inhibits non-TLR pathways
to IRF3 and 7 activation. Upon recognition of its RNA through
RIG-I, sendai virus (SeV) activates IRF3 and 7, and conse-
quently induces the Ifnb promoter (Kato et al, 2005).
Infection of cells with SeV led to induction of the Ifnb
promoter, which was strongly inhibited by K7, but not A52
(Figure 3C). To define the site of action of K7 on this pathway,
we examined the effect of K7 on each of the steps outlined in
Figure 3H. To this end, we activated a reporter gene under the
control of the IFN-stimulatory response element (ISRE) by
expressing the MAVS adaptor protein that links RIG-I to IRF3/
7. This was inhibited by K7 (Figure 3D). Downstream of
MAVS, TBK1 and IKKe directly phosphorylate IRF3 and 7,
which leads to their homo-dimerisation and activation
(McWhirter et al, 2004). K7 inhibited TBK1-induced activa-
tion of IRF3 (not shown) and IRF7 (Figure 3E), and IKKe-
induced IRF7 activation (Figure 3F), suggesting that K7 exerts
an effect on TBK1/IKKe or further downstream. Consistent
with this, K7 inhibited TBK1-induced ISRE activation,
whereas direct induction of the ISRE by IRF7 expression
was unaffected (Figure 3G). This pinpoints the inhibitory
effect of K7 to the events around the activation of IRF3/7 by
TBK1/IKKe (as shown by an asterisk in Figure 3H). K7 also
inhibited SeV-stimulated IRF3 transactivation (Figure 3I).
Further, SeV induced the appearance of higher molecular
weight bands of endogenous IRF3, which represent
phosphorylated forms. This was inhibited by K7, as was
the appearance of virus-induced phospho-Ser396 IRF3
(Figure 3I). Thus, K7 can inhibit phosphorylation of endo-
genous IRF3.
K7 targets the host DEAD box protein DDX3
The inhibitory effects of K7 on IRF activation cannot be
explained by its interaction with IRAK2 and TRAF6. We
also failed to show an interaction between K7 and IKKe
and/or TBK1 in co-immunoprecipitation experiments (not
shown). Therefore, we reasoned that K7 must have additional
host target(s) that can explain its ability to inhibit TBK1/
IKKe-mediated IRF3/7 activation. To identify these, we used
recombinant His-tagged K7 protein to isolate interacting
proteins from HEK293 cell lysates and analysed these by
SDS–PAGE. In a one-dimensional Coomassie-stained gel, we
detected a band of approximately 70 kDa that appeared
reproducibly in the K7 pull-down lane but not in the control
lane (Figure 4A). This band was identified by peptide mass
fingerprinting as DDX3 (also called DBX or Cap-Rf), a DEAD
box-containing putative RNA helicase of 73 kDa. Human
DDX3 and/or its orthologues have been implicated in several
different cellular processes, including control of cell growth,
translational control and nuclear–cytoplasmic shuttling (see
Introduction).
To confirm the K7–DDX3 interaction by an alternative
method and to test whether DDX3 was a K7-specific target,
HA-tagged K7 or A52 was transfected into HEK293T cells and
co-immunoprecipitation experiments were performed.
Endogenous DDX3 co-precipitated with HA–K7 (Figure 4B,
upper panel, lane 2), but not with A52 (Figure 4B, upper
panel, lane 4). Also, in VACV-infected cells, Myc-tagged DDX3
Figure 2 K7 inhibits TLR-induced NF-kB activation. In (A–C), HEK293 cells were transfected with pRK5-K7R or empty vector and the NF-kB
luciferase reporter gene. Cells were stimulated with 20 ng/ml IL-1b for 6 h (A), transfected with 50ng of CD4TLR4 for 24 h (B) or HEK293-TLR3
cells were stimulated with 25mg/ml poly(I:C) for 8 h (C). Data are expressed as the mean fold induction±s.d. relative to control levels, for a
representative experiment of three, each performed in triplicate. (D, E) For agonist-induced cytokines, HEK-TLR4 (D) or HEK-TLR3 (E) cells
were transfected with K7R 24h prior to stimulation with 1mg/ml LPS or 25 mg/ml poly(I:C), respectively. After 24 h, supernatants were assayed
for IL-8 (D) or RANTES (E) by ELISA. The experiments were performed four times in triplicate and data are expressed as the mean±s.d. from
one representative experiment. (F) HEK293Tcells were transfected with pCMV-HA-K7R and IRAK2-Myc and 48 h later, lysates were subjected to
immunoprecipitation (IP) analysis with the indicated antibodies. (G) HEK293T cells were transfected with pCMV-HA-K7R and Flag–TRAF1, 2,
3, 4, 5 or 6 and 48h later, lysates were subjected to IP analysis with the indicated antibodies. Results shown are representative of at least three
experiments.
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Figure 3 K7 inhibits IRF activation at the level of TBK1/IKKe. In (A–G), HEK293 cells were transfected with pRK5-K7R or pRK5-A52R, together
with the indicated luciferase reporter genes for 24 h. Data are expressed as the mean fold induction±s.d. relative to control levels, for a
representative experiment of at least two, each performed in triplicate. (A, B) Cells were transfected with IRF7-GAL4 (A) or IRF3-GAL4 (B)
expression plasmids, and the GAL4-dependent pFR luciferase reporter gene plus 50 ng expression plasmid encoding TRIF. (C) Cells were
transfected with the Ifnb promoter reporter gene prior to sendai virus infection for 16 h. (D) Cells were transfected with the ISRE reporter gene
plus 50ng MAVS expression plasmid. (E, F) Cells were transfected with IRF7-GAL4 and the pFR luciferase reporter gene, plus 50 ng of either
TBK1 (E) or IKKe (F) expression plasmid. (G) Cells were transfected with the ISRE reporter gene plus 50ng of either TBK1 or IRF7 expression
construct for 24 h. (H) Schematic of SeV signalling pathway to Ifnb promoter induction. The deduced point of inhibition by K7 is marked with
an asterisk. (I) For the IRF transactivation assay, cells were transfected as in (B), followed by stimulation with SeV for 16 h (upper panel). For
immunoblot analysis, cells were transfected with K7, followed by SeV stimulation for 6 h. Western blots were probed for total IRF3 and
phosphorylated IRF3 (Ser396) (lower panel).
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co-immunoprecipitated with virally expressed K7 but not A52
(Figure 4C), confirming that DDX3 is a target for K7 but not
A52. Figure 4D shows that endogenous DDX3 co-immuno-
precipitated with K7 expressed during VACV infection, con-
firming that this interaction occurs with physiological levels
of both proteins.
K7 can interact with DDX3 in the cytoplasm and nucleus
It has been reported that DDX3 shuttles between the cyto-
plasm and the nucleus, and that it is exported from the
nucleus through the CRM-1 system (Yedavalli et al, 2004).
We confirmed this property of DDX3 by immunoblot analysis
of subcellular fractions: in the absence of the CRM-1 inhibitor
leptomycin B (LMB) DDX3 was detected mostly in the
cytoplasmic fraction, whereas treatment with LMB led to its
accumulation in the nucleus (Figure 4E). This result was also
confirmed by immunofluorescent staining of HA-tagged
DDX3. In the absence of LMB, DDX3 was located in the
cytoplasm and cannot be detected in the nucleus with this
method. However, 4 h after the addition of LMB, DDX3 was
largely only detected in the nucleus (Figure 4F).
We then wanted to determine whether K7 interacts with
DDX3 in the cytoplasm, the nucleus or both. To this end, we
cloned K7 into an expression vector that generates a K7–EYFP
(enhanced yellow fluorescent protein) fusion protein. When
we analysed the cellular localisation of K7–EYFP (Figure 4G)
or HA-tagged K7 that was stained with a fluorescently
labelled antibody against the HA tag (not shown), K7 was
present in both the cytoplasm and the nucleus. In the absence
of LMB, K7 and DDX3 colocalised in distinct regions of the
cytoplasm (Figure 4G, left column). After CRM-1 inhibition
by LMB, DDX3 accumulated in the nucleus where it again
colocalised with K7 (Figure 4G, right column). As a control
for our experimental set-up, we co-expressed A52–EYFP and
DDX3 and found no colocalisation of A52 and DDX3 (not
shown). Our data suggest that K7 and DDX3 can interact in
the cytoplasm. The observed colocalisation in the nucleus
could be real or due to the high levels of both proteins in the
nucleus after LMB treatment.
DDX3 is a positive effector of the IRF pathway
at the level of TBK1/IKKe
On the basis of our finding that K7 and not A52 can inhibit
IRF activation and the identification of DDX3 as a K7-specific
target, we wondered whether DDX3 itself has a role in this
pathway. Ectopic expression of DDX3 alone led to some Ifnb
Figure 4 K7 but not A52 interacts with DDX3. (A) HEK293 cell lysates were added to purified His–K7 coupled to Ni-Agarose and incubated for
2 h at 41C. The immune complexes were precipitated, subjected to SDS–PAGE and stained with Coomassie blue. A band of approximately
70 kDa (marked with an arrow) that appeared specifically in the K7 pull-down lane was excised, prepared for MALDI-TOF analysis and shown
to be DDX3. (B) HEK293T cells were transfected with HA–K7R, A52R or empty vector (EV) and 48 h later, lysates were subjected to
immunoprecipitation analysis to detect endogenous DDX3. (C) HEK293 cells were transfected with Myc–DDX3 expression plasmid. After 24 h
cells were mock infected or infected with WR at 10 p.f.u. per cell, and 8h later lysates were subjected to immunoprecipitation analysis with
K7- or A52-specific antiserum LC: antibody light chain. (D) HEK293 cells were mock infected or infected with WR at 10 p.f.u. per cell and 8h later,
cell lysates were subjected to immunoprecipitation with K7-specific antiserum, followed by immunoblotting with the indicated antibodies.
(E) HEK293 cells were either left untreated or incubated with 25mM leptomycin B (LMB) for 4h. Cytoplasmic (Cy) and nuclear (N) extracts were
analysed for DDX3 by immunoblotting. (F) HEK293 cells were grown on 22-mm coverslips in six-well plates and transfected with the HA–DDX3
expression plasmid for 48 h and then 25mM LMB was added. Cells were fixed 4 h later, permeabilised and stained with anti-HA-AlexaFluor594
and the DAPI nuclear stain. The slides were examined by phase-contrast and confocal microscopy. A section of approximately 1mm through the
centre of a cell is shown. (G) HEK293 cells were grown as in (F) and transfected with HA–DDX3 and K7–EYFP expression plasmids for 48 h.
LMB (25mM) was then added and the cells were fixed 4 h later, permeabilised and stained with anti-HA-AlexaFluor594 and DAPI. The slides
were examined by phase contrast and confocal microscopy. A section of approximately 1mm through the centre of cells is shown. Results
shown for (A–G) are representative of at least two experiments.
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promoter induction, whereas it strongly enhanced Ifnb pro-
moter induction in response to SeV infection (Figure 5A), as
opposed to the inhibitory effect observed for K7 expression
(Figure 3C). Similar to the inhibitory effect of K7, the positive
effect of DDX3 on Ifnb promoter induction localised to the
level of TBK1/IKKe, as DDX3 expression also enhanced
TBK1- and IKKe-mediated Ifnb promoter induction (Figure
5B and C). Given that DDX3 is a helicase, we wondered
whether this activity was important for its ability to stimulate
the Ifnb promoter. To address this, we generated a DDX3
point mutant by changing lysine at position 230 in a critical
ATPase motif to glutamic acid. This K230E mutant has
previously been shown to lose the ability to hydrolyse ATP
and unwind RNA (Yedavalli et al, 2004). The expression of
K230E enhanced activation of the Ifnb promoter by IKKe as
potently as wild-type DDX3 (compare Figure 5C and D),
suggesting that the effect of DDX3 on Ifnb promoter induction
is independent of its ATPase/helicase activity.
The N-terminus of DDX3 is required for Ifnb promoter
induction and confers K7 binding
DEAD box helicases display a relatively high degree of
sequence similarity across the two central RecA-like domains
that contain the conserved helicase motifs. However, the N-
and C-terminal flanking regions are more divergent and
thought to confer specificity of function (Hogbom et al,
2007). As the ATPase and helicase activity of DDX3 seemed
to be dispensable for its effect on the Ifnb promoter
(Figure 5D), we wondered whether the N- and C-terminal
regions mediate this novel function of DDX3. Hence, we
generated DDX3 truncation mutants that were either lacking
the C-terminal (1–572), the N-terminal (139–662) flanking
region or both (139–572). Further truncations were made that
divide the protein between the two RecA domains: 1–408 and
409–662.
When we analysed these mutants for their effects on IKKe-
induced Ifnb promoter induction, we found that the C-term-
inal truncations (1–572, 1–408) enhanced promoter induction
similar to the full-length DDX3 (1–662) (Figure 5E, black
bars). However, all the mutants truncated at the N-terminus
(409–662, 139–662 and 139–572) failed to enhance Ifnb
promoter induction and even had inhibitory effects
(Figure 5E, grey bars). These data show that the N-terminal
region between aa 1–139 is required for the positive effect of
DDX3 on Ifnb promoter induction.
Interestingly, we found that this region of DDX3 also
confers binding to K7. This was demonstrated using recom-
binant His-tagged truncation mutants of DDX3 that corre-
spond to the expression plasmids used for studying the
effects on the Ifnb promoter. With His-tagged full-length
DDX3 and the truncated DDX3 versions, we performed pull-
down assays with cell lysates from HEK293T cells that had
Figure 5 Role for the N terminus of DDX3 in TBK1/IKKe-induced Ifnb promoter activation. In (A–C), HEK293 cells were transfected with the
indicated amount of pCMV-Myc-DDX3 (nanograms) together with the Ifnb promoter reporter gene, cells were harvested after 24 h and
luciferase reporter gene activity was measured. (A) Cells were infected with sendai virus for 16 h. (B) Cells were transfected with 50ng TBK1
expression plasmid. (C) Cells were transfected with 50ng IKKe expression plasmid. (D) Cells were transfected with the Ifnb promoter reporter
gene, together with 50 ng IKKe and the indicated amount (nanograms) of an expression plasmid encoding a mutant version of DDX3 lacking
ATPase activity (K230E). (E) Cells were transfected with the Ifnb promoter reporter gene, together with 50ng IKKe and 50 or 100ng of
expression vectors encoding full-length DDX3 (1–662) or the indicated N- and/or C-terminally truncated DDX3 proteins. Expression of DDX3
truncations by immunoblot is also shown. For (A–E), data are expressed as the mean fold induction±s.d. relative to control levels, for a
representative experiment of at least two, each performed in triplicate. (F) Either full-length recombinant His-tagged DDX3 (1–662) or different
His-tagged truncated DDX3 proteins were used in pull-down assays with cell lysates from HEK293Tcells transfected with the HA–K7 expression
plasmid. The precipitates were then analysed by immunoblotting with anti-HA antibody. Results are representative of three experiments.
(G) Schematic of DDX3 showing in grey the positions of the nuclear export sequence (NES) and the conserved ATPase/helicase domain. The DEAD
motif and the GKT motif that was mutated in the K230E point mutant are also indicated. A schematic summarising the different truncation
mutants of DDX3 and their abilities to stimulate Ifnb promoter activation and to bind to K7, both of which depend on the presence of the
N-terminus of DDX3 (aa 1–139), is shown below. (H) The N-terminus of DDX3 (aa 1–139) was expressed as a His-tagged recombinant protein
and used in pull-down assays with cell lysates from HEK293Tcells transfected with HA–K7. The precipitates were analysed by immunoblotting
with anti-HA antibody. Result is representative of two experiments.
A role for DDX3 in IRF activation
M Schro¨der et al
The EMBO Journal VOL 27 | NO 15 | 2008 &2008 European Molecular Biology Organization2152
been transfected with HA–K7. Full-length DDX3 as well
as DDX3(1–408) interacted with K7, whereas the DDX3
truncations lacking the N terminus (409–662, 139–572 and
139–408) failed to bind K7 (Figure 5F). These data strongly
suggest that K7 binds to the N-terminal region of DDX3 (aa 1–
139) that is required for the enhancement of the Ifnb promo-
ter. This correlation is summarised in Figure 5G.
To further confirm that K7 targets the N-terminal region of
DDX3, we generated recombinant His-tagged DDX3 compris-
ing only aa 1–139 and repeated the pull-down experiment. As
shown in Figure 5H, the N-terminus of DDX3(1–139) was
sufficient for K7 binding.
The N-terminus of DDX3 exerts an effect as a dominant
negative to suppress IRF-dependent promoter induction
As the N-terminal region of DDX3 seemed to be crucial for its
positive effect on the Ifnb promoter, we wondered whether
the expression of DDX3(1–139) would have a dominant-
negative effect. Indeed, co-expression of DDX3(1–139) inhi-
bited IKKe-induced activation of the Ifnb promoter (Figure 6A,
black bars) and reversed the enhancement observed with the
expression of full-length DDX3 (Figure 6A, white and grey
bars). This suggested that the N-terminus of DDX3 might be
able to inhibit DDX3 function in other TBK1/IKKe-dependent
pathways that involve endogenous DDX3. Hence, we exam-
ined the effect of DDX3(1–139) on different PRR pathways
leading to the induction of the IRF3-dependent promoter Ccl5
(RANTES). Figure 6B shows that SeV (through RIG-I),
poly(I:C) (through mda-5) and poly (dA:dT) (through the
cytoplasmic DNA receptor(s)), all induced the Ccl5 promoter.
In each case, this was inhibited by the expression of DDX3
(1–139). In contrast, full-length DDX3 enhanced promoter
induction (Figure 6B). SeV- or IKKe-stimulated IRF3
activation was also inhibited by DDX3(1–139) (Figure 6C),
confirming an effect on IRF activation. These data suggest a
requirement for DDX3 for full induction of IRF-dependent
promoters activated by PRR signalling.
RNAi depletion of DDX3 inhibits
TBK1- and IKKe-mediated Ifnb promoter induction
To confirm the role of endogenous DDX3 in TBK1/IKKe-
mediated IRF-dependent promoter induction, we suppressed
endogenous DDX3 expression using RNAi. Two oligonucleo-
tides specifically targeting Ddx3 led to a significant reduction
in DDX3 protein expression when compared to cells trans-
fected with a control oligonucleotide (Figure 6D). Similar to
previous investigators (Yedavalli et al, 2004), we found it
difficult to achieve complete knockdown of DDX3 protein
Figure 6 DDX3 is required for TBK1/IKKe-dependent promoters and is recruited to IKKe. (A) HEK293 cells were transfected with the indicated
amount (nanograms) of pCMV-DDX3 and/or pCMV-DDX3(1–139), 50ng IKKe expression plasmid and the Ifnb promoter reporter gene.
(B) Cells were transfected with a Ccl5 (RANTES) promoter reporter gene and the indicated amount (nanograms) of either pCMV-DDX3 or
pCMV-DDX3(1–139) 24 h prior to stimulation with sendai virus or transfection with either poly(I:C) (5mg per well) or poly(dA:dT) (1mg per
well). Cells were harvested 16h later. (C) Cells were transfected with 0 or 100ng pCMV-DDX3(1–139) together with the IRF3 reporter genes,
and either infected with sendai virus (left panel) or transfected with IKKe (right panel). (D) DDX3 expression was suppressed using two
different RNAi oligonucleotides, DDX3-1 and DDX3-2. HEK293 cells were transfected on two consecutive days with the DDX3 RNAi
oligonucleotides or a control oligonucleotide matched for GC content. At 48 h after the second transfection, the cell lysates were analysed
by immunoblotting with the indicated antibodies to confirm the reduction of endogenous DDX3 protein levels (left panel). HEK293 cells were
co-transfected with the Ifnb promoter reporter gene and 50 ng expression plasmid for either TBK1 (middle panel) or IKKe (right panel) during
the second transfection with RNAi oligonucleotides. (E) Similar to (D), except cells were transfected with IRF3 reporter genes and stimulated
with sendai virus (left panel) or poly(I:C) (right panel). In (A–E), reporter gene activity was measured and data are expressed as the mean fold
induction±s.d. relative to control levels, for a representative experiment of at least three, each performed in triplicate. (F) HEK293Tcells were
transfected with Myc–DDX3 and Flag–IKKe for 48 h and the lysates were analysed by immunoprecipitation (IP) with the indicated antibodies.
(G) Recombinant His–DDX3(1–139) was used in ‘pull-down’ assays with lysates from HEK293T cells transfected with Flag–IKKe. The
precipitates were analysed by immunoblotting with Flag Ab. (H) HEK293Tcells were infected with sendai virus and samples were harvested at
the indicated times after virus infection. The cell lysates were prepared, immunoprecipitated with anti-IKKe antibody and analysed by
immunoblotting with the indicated antibodies. All results are representative of two or more experiments.
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expression, which may be due to the high levels of DDX3 in
the cell and/or the stability of the protein. Nonetheless, we
observed reduced TBK1- and IKKe-induced activation of
the Ifnb promoter when endogenous DDX3 expression
was reduced by either RNAi oligonucleotide (Figure 6D).
Furthermore, DDX3 RNAi inhibited SeV- or poly(I:C)-
stimulated IRF3 activation (Figure 6E). This provides further
evidence for the involvement of endogenous DDX3 in
TBK1/IKKe-mediated activation of IRF3.
DDX3 interacts with IKKe in a virus-dependent manner
Our data so far consistently pointed to the involvement of
DDX3 in the activation of IRF3/7 by TBK1/IKKe, but it
remained to be determined whether DDX3 was actually part
of this signalling complex. To address this, the interaction
between Flag–IKKe and Myc–DDX3 was tested in a co-
immunoprecipitation assay, where Myc–DDX3 co-immuno-
precipitated with Flag–IKKe (Figure 6F). Interestingly, in the
presence of IKKe, we also observed a higher molecular weight
form of DDX3 in the cell lysates (Figure 6F, middle panel),
which might represent a phosphorylated form of DDX3.
As it is the N-terminal region of DDX3 that mediates the
positive effect on the Ifnb promoter, we wondered
whether IKKe binds to this region of DDX3. In a pull-down
assay with recombinant His–DDX3(1–139), we found that
IKKe can indeed bind to the isolated N-terminus of DDX3
(Figure 6G). IKKe binding could provide a molecular expla-
nation for the requirement of this DDX3 region for the effect
on the Ifnb promoter.
To confirm the physiological relevance of the interaction
between DDX3 and IKKe for PRR signalling, we infected
HEK293T cells with SeV for different periods of time, and
demonstrated a virus-induced transient association between
endogenous DDX3 and endogenous IKKe (Figure 6H). This
suggests that the detection of virus by a PRR induces the
formation of a signalling complex containing IKKe and DDX3,
thus providing further evidence implicating DDX3 in the
pathway from PRRs to IRF activation and promoter induction.
Discussion
In this study, we demonstrate a novel function for DDX3 in
innate immunity, namely as a positive regulator of
TBK1/IKKe-mediated IRF activation. This novel function of
DDX3 was revealed through the characterisation of the effect
of the VACV protein K7 on host signalling pathways. Our
interest in K7 stemmed from the fact that it shares significant
sequence similarity with A52, a well-characterised inhibitor
of the TLR–NF-kB signalling axis, which interacts with IRAK2
and TRAF6. As might be expected, K7 also targeted IRAK2
and TRAF6 and inhibited TLR-induced NF-kB activation.
However, given the lack of effect of A52 on PRR pathways
to IRF3 and 7 activation, it was surprising that K7 inhibited
PRR signalling pathways to IRF3 and 7 activation, ISRE
stimulation and Ifnb promoter induction.
We localised the inhibitory effect of K7 to TBK1/IKKe-
mediated IRF activation, a point of convergence for many
different PRR pathways that activate IRF3 and 7. Inhibiting
TLR-independent pathways to Ifnb is likely to be relevant for
VACV, a dsDNA virus that replicates in the cytoplasm and
generates significant amounts of dsRNA (Weber et al, 2006).
In fact, there is evidence that VACVengages TLR-independent
pathways leading to IFN induction (Waibler et al, 2007; Zhu
et al, 2007). Hence, it is also likely that VACV has developed
counteracting strategies to evade these pathways and K7
appears to represent one such strategy. Given that TRAF6
and IRAK2 are not involved in TLR-independent IRF activa-
tion, we suspected that K7 targets an additional protein
required for signalling to IRF activation, and subsequently
identified DDX3 as such.
We provide several lines of evidence for a role for DDX3 in
IRF activation: (1) DDX3 expression enhanced SeV-stimulated
Ifnb promoter induction; (2) the N-terminal region of DDX3
was required for this effect and when expressed in isolation
acted as a dominant negative to inhibit ligand-induced IRF3
and IRF3-dependent promoters; (3) knockdown of endogen-
ous DDX3 expression by RNAi inhibited Ifnb promoter in-
duction by TBK1 or IKKe, and SeV- or poly(I:C)-stimulated
IRF3 activation; (4) IKKe interacted with the functionally
important N-terminus of DDX3 and (5) The association of
DDX3 with IKKe was inducible by SeV stimulation, linking
DDX3 into the signalling pathway leading from RIG-I engage-
ment to IRF activation.
The role of DDX3 in IRF activation in vivo remains to be
confirmed by use of a DDX3 knockout mouse, as siRNA and
classical transfection studies may not fully reflect the true in
vivo role. Nonetheless, the virus-induced association between
endogenous DDX3 and IKKe in human cells shown here
strongly supports a signalling role for DDX3.
We also provide evidence that K7 targets this function of
DDX3 to interfere with IRF activation, as DDX3 exerted its
stimulatory effect at the level of TBK1/IKKe, which correlated
with the point of inhibition by K7. Further, K7 bound to the
N-terminal region of DDX3 that is required for Ifnb promoter
induction. This is the first time a DEAD box helicase has
been implicated in the regulation of an innate immune
signalling pathway at the level of transcription factor activa-
tion by upstream kinases, although the distantly related
DExD/H helicases RIG-I and mda-5 exert an effect further
upstream as PRRs. Interestingly, DDX3 expression was shown
to be induced in an IRF7-dependent manner (Barnes et al,
2004), an observation that further links DDX3 and the IRF
pathway.
Prior to this study, an array of divergent cellular functions
for human DDX3 and/or its orthologues have been reported,
such as regulation of splicing and nuclear export of RNA
(Rosner and Rinkevich, 2007). Recently, a positive role for
DDX3 in cancer biogenesis has been suggested (Botlagunta
et al, 2008). However, DDX3 had previously been proposed as
a tumour suppressor due to its inhibitory effect on the
translation initiation factor eIF4e (Shih et al, 2008). Still,
DDX3 has been shown to upregulate p21 promoter activity by
interacting with the Sp1 transcription factor and to enhance
p21/waf1 protein expression (Chao et al, 2006). This latter
finding is more in line with our discovery that DDX3 can
upregulate Ifnb promoter induction through IRFs by interact-
ing with IKKe. Interestingly, an emerging theme is that many
DEAD box proteins are multifunctional and have roles in
transcriptional regulation that are often independent of their
helicase activity (Fuller-Pace, 2006). Consistent with this, we
found that the positive effect of DDX3 on the Ifnb promoter is
independent of its ATPase and unwinding activities. It is of
note that the N-terminus of DDX3 is required for its role in
IRF activation, as this region is very divergent in DEAD box
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helicases and is thought to confer functional specificity. It
remains unclear how exactly the association of DDX3 and
IKKe translates into enhanced IRF and promoter activation.
The DDX3 N-terminus contains large numbers of serine
clusters, and we observed a higher molecular weight form
of DDX3 when co-expressed with IKKe. This might suggest
that DDX3 is phosphorylated by IKKe. Other interesting
features contained within the DDX3 N-terminal region are
its nuclear export sequence (aa 11–21) and the recently
described property to bind eIF4e (aa 38–44) (Shih et al,
2008). It is hence becoming clear that DDX3 has multiple
different and distinct cellular functions involving different
domains of DDX3, and our understanding of these functions
is still fragmentary. Further research should investigate the
interplay between the different functions and try to reconcile
some of its seemingly contradictory effects.
Strikingly, other viral proteins also target DDX3: HIV Rev
protein exploits the nuclear–cytoplasmic shuttling function of
DDX3 to export virally encoded mRNAs out of the nucleus
(Yedavalli et al, 2004). In contrast, VACV replicates in the
cytoplasm and has therefore no requirement to subvert
nuclear RNA export. It is unclear what the functional con-
sequences of the HCV Core protein–DDX3 interaction are;
however, it has recently been shown that DDX3 is required
for HCV replication (Ariumi et al, 2007). K7 seems to target
DDX3 in a different way compared to these two other viral
proteins, namely by disrupting the ability of DDX3 to enhance
IRF activation by binding the functionally important N termi-
nus. Neither Rev nor the Core protein binds to DDX3 within
the N-terminal region. Also, HIV and HCV seem to subvert
rather than inhibit DDX3, considering that DDX3 is required
for HIV and HCV replication. It is possible that by recruiting
DDX3 for the purpose of nuclear export of viral mRNAs and/
or viral replication, these viruses simultaneously sequester
DDX3 away from its positive effector role in the IRF pathway
and are hence benefiting in two different ways from targeting
DDX3.
Because of its requirement for HIV and HCV replication,
DDX3 has been suggested as an antiviral drug target, as
inhibition of DDX3 might block replication of these viruses
(Kwong et al, 2005). However, in the light of our findings this
strategy should be carefully assessed, as disruption of DDX3
would also impair the induction of antiviral mediators that
depend on IRF activation. In conclusion, we have shown a
novel positive role for a DEAD box protein in IRF activation
by TBK1/IKKe. This study should further the interest in DDX3
by drawing attention to its novel role in innate immunity.
More in-depth studies of how DDX3 regulates IRF activation
and of the mechanism whereby K7 inhibits DDX3 function
are underway and should provide us with valuable informa-
tion for manipulating DDX3 function in the future.
Materials and methods
Plasmids
Sources of expression plasmids were Flag–TRAF6 and Flag–TRAF2
(Tularik Inc., San Francisco, CA), CD4-TLR4 (R Medzhitov, Yale
University, CT), Flag–TRIF (S Akira, Osaka University, Osaka,
Japan), Myc–MyD88 (L O’Neill, Trinity College Dublin, Dublin,
Ireland), TBK1–Flag, IKKe–Flag (K Fitzgerald, University of
Massachusetts Medical School, Worcester, MA) and MAVS (Z Chen,
University of Texas, TX). K7R was amplified from genomic DNA of
the VACV strain WR and the PCR product was cloned into pCMV-HA
to make pCMV-HA-K7R. HA–K7R was also subcloned into pRK5
mammalian expression vector. For bacterial expression of His-
tagged K7, K7R was subcloned into pHisParallel2. DDX3 was
amplified from human PBMC cDNA and the PCR product was
cloned into the pCMV-Myc and pCMV-HA mammalian expression
vectors (BD Biosciences) and into pHisParallel2 for bacterial
expression of His-tagged DDX3. For generating K7–EYFP fusion
protein, K7R was cloned into pCDNA (Invitrogen) containing the
EYFP ORF (provided by K Kroeger, WAIMR, Perth, Australia).
Antibodies and reagents
Anti-K7 polyclonal Ab was raised against purified full-length
recombinant K7 expressed from pHisparallel2-K7R in Escherichia
coli (Inbiolabs). Other antibodies used were anti-Flag M2mAb,
anti-Flag M2-conjugated agarose, anti-Myc mAb clone 9E10 (all
from Sigma), anti-HA mAb (Covance), anti-DDX3 clone BL1649
(Bethyl Laboratories, Montgomery, TX, USA), anti-IKKe (Abcam,
Cambridge, UK), anti-IRF3 (IBL) anti-phospho-Ser396-IRF3
(Cell Signaling Technologies) and anti-A52 (Harte et al, 2003).
Human rIL-1b was a gift from the National Cancer Institute
(Frederick, WA). Poly(I:C) and poly(dA:dT) were from Amersham.
SeV was kindly provided by Ilkka Julkunen (National Public Health
Institute, Finland).
Reporter gene assays
Promoter induction and transcription factor activation were
measured using HEK293 cells (2104 cells per well) seeded onto
96-well plates and transfected 24h later with expression vectors and
luciferase reporter genes (Maloney et al, 2005; Stack et al, 2005).
Data are expressed as the mean fold induction±s.d. relative to
control levels, for an individual experiment performed in triplicate.
A representative of at least three independent experiments is
shown.
Immunoprecipitation and immunoblotting
Co-immunoprecipitations were performed in HEK293T cells
(1.5106 cells) seeded in 10-cm dishes (Stack et al, 2005). The
immune complexes were analysed by SDS–PAGE and immunoblot-
ting. For analysis of the kinetics of K7 expression, confluent
monolayers of HEK293 cells were infected at 10 p.f.u. VACV per cell
for 60min at 371C.
His pull-down assays
Bacterial expression constructs were transformed into E. coli BL21
(DE3). Protein expression was induced with IPTG, and proteins
were purified using Ni-Agarose (Sigma). For pull-down experi-
ments, equal amounts of the different His fusion proteins were used
as determined by SDS–PAGE and Coomassie staining. Cell lysate
from transfected HEK293 cells was incubated with the purified His
fusion proteins coupled to Ni-Agarose. The complexes were
precipitated and subjected to SDS–PAGE. For the identification of
K7-interacting proteins, specific bands were cut out of the
Coomassie-stained gel and prepared for MALDI-TOF analysis. For
all other pull-down experiments, gels were transferred to PVDF
membranes and subjected to immunoblotting.
MALDI-TOF
Bands were cut from Coomassie-stained SDS–PAGE gels and
digested with 10mg/ml modified trypsin (Promega) overnight at
371C. Peptides were extracted and samples were analysed by
MALDI-TOF. The resulting peak list was searched against the NCBI
non-redundant protein database using the Mascot search engine.
DDX3 was identified with a probability-based Mowse score of 120.
Determination of cytokine concentrations
LPS-induced IL-8 and poly(I:C)-induced RANTES production in
HEK293 clonal cell lines expressing either TLR4 and MD-2 (HEK-
TLR4) or TLR3 (HEK-TLR3) was measured by ELISA.
Confocal imaging
HEK293 cells were grown on 22-mm coverslips in six-well plates
and transfected with 2.3mg of total DNA. At 48 h after transfection,
cells were fixed with 4% paraformaldeyde, permeabilised with
0.5% Triton-X-100 and stained with anti-HA-AlexaFluor594 and
DAPI nuclear stain. Slides were examined by phase-contrast and
confocal microscopy with an Olympus Fluoview FV1000 Imaging
system using a  60 objective and 2- to 3-fold digital zoom. Images
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were collected with Kalman integration and processed with the
Olympus Fluoview software (Version 1.3c).
siRNA gene silencing
For silencing of endogenous human DDX3, two different StealthTM
RNAi oligonucleotides were employed: DDX3-1 50-GGGA-
GAAAUUAUCAUGGGAAACAUU-30 (HSS102712) and DDX3-2
50-UUCAACAAGAAGAUCCAACAAAUCC-30 (HSS102713) along with
a control oligonucleotide of a matched GC content (36% GC)
(Invitrogen). HEK293 cells were transfected with the RNAi duplexes
using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. This transfection was repeated after 24 h and
cells were harvested 24h after the second transfection. The cell
lysates were prepared and analysed by SDS–PAGE and immuno-
blotting. For reporter gene assays, HEK293 cells in 96-well plates
(2104 cells per well) were transfected with siRNA duplexes and
then co-transfected with reporter and expression constructs (or
stimulated with SeV or poly(I:C)) and a second dose of siRNA 24h
later. Reporter gene induction was analysed 24h after the second
transfection.
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